We are a world leading pharmaceutical company with a world-class biologics capability. Backed by strong science and wide-ranging commercial skills, we are committed to sustainable development of our business and the delivery of a flow of new medicines that make a difference in the lives of patients and create value for our shareholders and society.
We focus our resources on six therapy areas where we believe our skills and resources can make the most difference. These areas include some of the world's most serious illnesses and together represent a major worldwide burden of disease: cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory & inflammation. We have a broad product range, including many world leaders and a number of key products: Arimidex, Crestor, Nexium, Seroquel and Symbicort.
We are active in over 100 countries with a growing presence in important emerging markets including China; corporate office in London, UK; and major R&D sites in Sweden, the UK and the US. We employ over 65,000 people (51% in Europe, 32% in the Americas and 17% in Asia, Africa and Australasia). Sales in 2008 totalled $31.6 billion. R&D investment totalled over $5 billion. We have around 12,000 people in our R&D organisation and 17 principal R&D centres in eight countries. We have 26 manufacturing sites in 18 countries. Alongside our commitment to competitiveness and performance, we continue to be led by our core values to achieve sustainable success.